Every 10-Q that Retractable Tech (RVP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVP filings page.
Retractable Technologies, Inc. reported weaker core operating results but a headline profit for the quarter ended June 30, 2026. Quarterly sales were $7.2 million, down from $10.4 million a year earlier, as EasyPoint® needle volumes declined and customer ordering patterns shifted. Gross profit was minimal and the company recorded a loss from operations of $5.1 million, similar to the prior-year quarter and a $11.3 million operating loss for the first half.
Despite this, net income turned positive, driven by non-operating items. A $6.4 million realized gain on investment sales and $1.5 million in TIA income produced Q2 net income of $2.8 million, or $0.09 per diluted share, versus a small loss last year. Cash from operations was an outflow of $3.1 million in the first half, but liquidity is supported by $2.6 million in cash and $37.2 million in debt securities, representing 26.3% of total assets.
Tariffs remain a major headwind: as of August 1, 2026, most syringe and needle imports from China face a combined 112.5% tariff, pressuring margins and sourcing. Management is expanding domestic manufacturing, including adapting equipment for 0.5 mL syringes and has reduced headcount by about 16% to cut annual payroll by roughly $2.2 million. Disclosure controls and procedures were assessed as not effective due to previously reported material weaknesses, though remediation efforts are underway.
Retractable Technologies, Inc. reported a wider operating loss and negative gross margin for the quarter ended March 31, 2026 as tariffs, higher costs, and donations pressured results. Net sales were $7.2 million, down from $8.3 million a year earlier, with syringes representing 80.8% of revenue.
The company posted a gross loss of $0.8 million and a loss from operations of $6.2 million, compared with a $4.7 million operating loss in 2025. Net loss improved to $4.2 million from $10.5 million, aided by $1.5 million of Technology Investment Agreement income and a $0.2 million unrealized investment gain versus a $7.2 million loss last year.
Cash used in operations was $1.4 million, while $1.7 million was generated from investing activities, largely from net investment sales. The company held $32.9 million of debt and equity securities, or 23.9% of total assets, and $2.8 million of cash. Management expects tariffs of about 110% on many China-sourced syringes and needles to remain a material headwind and implemented a 16% workforce reduction in April 2026, targeting $2.2 million of annual payroll savings.
Retractable Technologies (RVP) filed its Q3 2025 10‑Q, reporting sales of $10,085,723 and net income of $371,047 (EPS $0.01). Gross profit was $1.69M with a loss from operations of $3.65M, offset by Other income – TIA of $1.52M and an unrealized gain on investments of $2.38M.
For the first nine months, sales were $28,826,629 with a net loss of $(10,217,140). Cash was $3.44M and investments at fair value were $30.50M; other long‑term liabilities related to the TIA were $59.40M. Three significant customers represented 57.3% of Q3 net sales.
The company highlighted tariff headwinds on China‑sourced syringes and needles, with prevailing rates at 130%. Tariff expense was $172K in Q3 and $2.3M year‑to‑date. Management is shifting more production to its U.S. facility, which raises payroll by about $825K annually but is expected to reduce tariff exposure. Inventory write‑downs were about $1.2M year‑to‑date. Shares outstanding were 29,937,159 as of November 3, 2025.
Retractable Technologies, Inc. (RVP) reported net sales of $10.45 million for the quarter and $18.74 million for the first six months of 2025, up from $6.03 million and $13.63 million a year earlier. Unit growth was driven by higher EasyPoint® needle volumes, but average selling prices fell due to product mix and distributor transaction fees, producing a small quarterly gross loss of $0.11 million and a six-month gross loss of $0.42 million.
The company recorded a six-month net loss of $10.59 million versus $13.74 million a year earlier. Investment holdings were $30.0 million at fair value (down from $40.3 million), producing a $5.6 million unrealized investment loss YTD. Cash totaled $3.04 million and inventories were $20.45 million. Other long-term liabilities under the Technology Investment Agreement (TIA) were $60.92 million. Tariffs from Chinese imports materially increased costs—approximately $2.1 million YTD—with second-quarter tariff expense of $561 thousand. The company received $1.9 million in litigation settlement proceeds and sold $5.0 million of securities to support operations.